SC 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

VACCINOGEN, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

918641101

(CUSIP Number)

Anders Ture Georg Halldin

Odlingsvagen 10, Alta Sweden SE-13836

46-708-687566

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 22, 2014

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Page 1 of 7 Pages)

CUSIP No. 918641101   13D Page 2 of 7 Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Anders Ture Georg Halldin
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) x (b) ¨
3.	SEC USE ONLY
4.	SOURCE OF FUNDS PF
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)	¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Sweden

NUMBER OF SHARES	7.	SOLE VOTING POWER 14,732,795
BENEFICIALLY OWNED BY	8.	SHARED VOTING POWER -
EACH REPORTING	9.	SOLE DISPOSITIVE POWER 14,732,795
PERSON WITH	10.	SHARED DISPOSITIVE POWER -

11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 14,732,795
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 31.4%
14.	TYPE OF REPORTING PERSON IN

CUSIP No. 918641101   13D Page 3 of 7 Pages

Item 1. Security and Issuer

This Schedule 13D relates to shares of common stock, par value $0.0001 per share, of Vaccinogen, Inc., a Maryland corporation (the “Issuer”). The principal office of the Issuer is located at 5300 Westview Drive, Suite 406, Frederick, MD 21703.

Item 2. Identity and Background

This Schedule 13D is filed Anders Ture Georg Halldin. Mr. Halldin is a citizen of Sweden and his address is Odlingsvagen 10, Alta, Sweden. Mr. Halldin is a director of the Issuer (see Item 1 for information regarding the Issuer). Mr. Halldin is self-employed and is principally engaged in the business of investing in securities.

Mr. Halldin has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and was not, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration

Investment funds provided by future investors who join TIS will be used to purchase the securities discussed in Item 4. Mr. Halldin may also use personal business funds in the transaction.

All shares will be issued without registration in reliance on the exemption in Section 4(a)(2) of the Securities Act of 1933 and Rule 506 of Regulation D thereunder and/or Regulation S.

Item 4. Purpose of Transaction

The information set forth in Item 3 is incorporated by reference into this Item 4.

The Investment Syndicate (“TIS”) was formed by Mr. Halldin, Stephen W. Robinson, Jeanne M. Robinson, and Eli Salazar (each a member of TIS) to acquire equity securities of the Issuer. On April 24, 2014, TIS and the Issuer entered into a binding agreement (as amended on August 22, 2014, the “Agreement”) pursuant to which TIS agreed to purchase (a) up to 3,636,362 units (“Units”), each Unit consisting of one share of the Issuer’s common stock and one warrant, exercisable for five years, to purchase three tenths (0.3) of a share of common stock at an exercise price of $6.05 per whole share, at $5.50 per Unit, for a total of up to $20,000,000, in the Issuer’s current Unit (Round C) offering, and (b) up to 10,909,090 shares of the Issuer’s common stock at $5.50 per share, for a total of up to an additional $60,000,000, all in up to five (5) closings, on the terms and conditions described therein. Each Unit contains anti-dilution rights providing for the issuance of additional shares of common stock as described in the 8-K Disclosure (defined below). In addition, under the Agreement, TIS has an option to purchase up to 5,454,545 shares of common stock at $5.50 per share, for a total of $30,000,000 for six months following the first closing. TIS’ obligation to purchase any Units or shares of common stock under the Agreement is subject to the satisfaction of various closing conditions, although TIS may waive any condition to a closing, and may make all or any of its total investment before the occurrence of any condition to closing, as detailed in the Forms 8-K filed by the Issuer with the SEC on April 28, 2014 and August 25, 2014 and the exhibits attached thereto (collectively, the “8-K Disclosure”).

CUSIP No. 918641101   13D Page 4 of 7 Pages

TIS intends to acquire control of the issuer through the purchase of equity securities and a restructuring of management, as further disclosed in the 8-K Disclosure. Each of Mr. Robinson and Mr. Salazar have entered into a Memorandum of Understanding with Mr. Halldin regarding their involvement in TIS.

Mr. Halldin and Mr. Robinson have also set forth certain terms regarding their investments in the Issuer in a binding term sheet dated August 20, 2014. Mr. Halldin wrote a put option, exercisable at any time, with an obligation to buy 1,869,159 shares of common stock, at a price of $5.35 per share from Mr. Robinson and Ms. Robinson. If such purchase had been made by August 31, 2014, Mr. Halldin would have received a warrant to purchase 272,727 shares of common stock, if such purchase is made between September 1, 2014 and September 15, 2014, Mr. Halldin will receive a warrant to purchase 136,363 shares of common stock, and if such purchase is made after September 15, 2014, Mr. Halldin will not receive any warrants. In connection with writing this put option, Mr. Halldin acquired a call option (right to buy), exercisable at any time, to buy the same securities on the same terms from Mr. Robinson and Ms. Robinson.

The terms of the TIS members’ current intentions with respect to TIS and the proposed transactions are set forth more fully in each of Mr. Robinson’s and Mr. Salazar’s Memorandum of Understanding, the Agreement, and the binding term sheet attached as exhibits hereto.

Except as set forth in this Schedule 13D, Mr. Halldin does not have any present plans, arrangements or understandings that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

(a) – (b) On August 22, 2014, Mr. Robinson and Ms. Robinson purchased 1,818,182 Units at $5.50 per Unit for $10,000,001. This investment included 1,869,159 shares of common stock (including Adjustment Shares) and warrants to purchase 545,454 shares of common stock. If the warrants are deemed to be exercised, and combining prior holdings, Mr. Robinson and Ms. Robinson are the joint direct beneficial owners of 2,950,620 shares of common stock and share voting and dispositive power over those shares.

Mr. Salazar is deemed to be the beneficial owner of the common stock he has the right to purchase under Rule 13d-3(d). Mr. Salazar has an option, excisable at any time, to buy: (1) 1,869,159 shares of common stock (including Adjustment Shares) and a warrant to purchase 545,454 shares of common stock, at a price of $5.50 per Unit, for a total of up to $10,000,000; and (2) up to 3,636,363 shares of common stock, at a price of $5.50 per share, for a total of up to $20,000,000. If the options are deemed to be exercised and the warrants are also deemed exercised, Mr. Salazar is deemed to be the direct beneficial owner of 6,050,976 shares of common stock and has sole voting and dispositive power over those shares.

CUSIP No. 918641101   13D Page 5 of 7 Pages

Mr. Halldin is deemed to be the beneficial owner of the remaining rights under the Agreement with TIS. Therefore, Mr. Halldin has options, exercisable at any time, to buy: (a) up to 7,272,727 shares of common stock, at a price of $5.50 per share; and (b) up to 5,454,545 shares of common stock, at a purchase price of $5.50 per share, although this option will expire on the sixth month anniversary of August 22, 2014. Mr. Halldin may also exercise, at his discretion, a call option to purchase from Mr. Robinson and Ms. Robinson 1,869,159 shares of common stock, at a price of $5.35 per shares. If the option is exercised by September 15, 2014, Mr. Halldin will receive a warrant to purchase 136,364 shares of common stock. If the options are deemed to be exercised and the warrant received thereby is also deemed exercised, Mr. Halldin is deemed to be the direct beneficial owner of 14,732,795 shares of common stock and has sole voting and dispositive power over those shares.

As of the date of this statement, the members of TIS listed above constitute a group within the meaning of Section 13(d)(3) of the Act. Together as a group, the TIS members are deemed to be the beneficial owners of the 21,728,868 shares of common stock held in the aggregate by the TIS members, representing 40.7% of the outstanding shares. According to information supplied by the Issuer to the TIS members, there were 34,027,592 shares of common stock outstanding as of August 22, 2014, together with the 19,323,702 shares underlying options and warrants deemed beneficially owned by the TIS members.

For purposes of this report, the TIS members have deemed the 19,323,702 shares converted pursuant to Rule 13d-3(d)(1)(i) because the shares were acquired in a transaction with the purpose of changing the control of the Issuer.

(c) Except as described herein, with respect to Mr. Halldin, there have been no transactions in the class of securities reported on that were effected during the past sixty days prior to the date of this filing. See Items 3 and 4 for more information, which is incorporated by reference in this Item 5.

(d) Except as described herein with respect to the shares held by Mr. Robinson and Ms. Robinson that Mr. Halldin has a right to purchase, no other person is known to have a right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock beneficially owned by Mr. Halldin.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

The information set forth in Items 3 and 4 are incorporated by reference into this Item 6.

Item 7. Material to be Filed as Exhibits

The following documents are filed as exhibits to this Schedule 13D:

Ex. 99.1 – Agreement between Vaccinogen, Inc. and The Investor Syndicate dated April 24, 2014 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed on April 28, 2014 by Vaccinogen, Inc.)

Ex. 99.2 – Amended Agreement between Vaccinogen, Inc. and The Investor Syndicate dated August 22, 2014 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed on August 25, 2014 by Vaccinogen, Inc.)

Ex. 99.3 – Memorandum of Understanding between Anders Halldin and Steve Robinson dated August 20, 2014.

CUSIP No. 918641101   13D Page 6 of 7 Pages

Ex. 99.4 – Memorandum of Understanding between Anders Halldin and Eli Salazar dated August 20, 2014.

Ex. 99.5– Term Sheet between Anders Halldin and Steve Robinson.

CUSIP No. 918641101   13D Page 7 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 2, 2014

/s/ Anders Ture Georg Halldin

Name: Anders Ture Georg Halldin

EX-99.3

Exhibit 99.3

IN WITNESS WHEREOF, the parties have executed this MOU on the day and year first above written.

/s/ Anders Halldin                 

Name: Anders Halldin

/s/ Steve Robinson               

Name: Steve Robinson

EX-99.4

Exhibit 99.4 

IN WITNESS WHEREOF, the parties have executed this MOU on the day and year first above written.

/s/ Anders Halldin                 

Name: Anders Halldin

/s/ Eli Salazar                  

Name: Eli Salazar

EX-99.5

Exhibit 99.5

Binding Term Sheet

For Stock Purchase Agreement Between

Steve Robinson (Seller) and Anders Halldin (Buyer)

August 20, 2014

Mr. Steven Robinson and Mr. Anders Halldin would execute the “Memorandum of Understanding” (MOU) that recognizes Mr. Robinson as a member of the TIS syndicate.

Mr. Robinson, as part of the TIS syndicate, purchases 1,818,182 shares of VGEN stock in the Series C at $5.50 per share. Total investment amount is $10,000,001.00. As part of that purchase, Mr. Robinson will be entitled to 545,455 warrants under the Series C terms. The Steven Robinson subscription of Vaccinogen shares is to take place on 8/21/14.

Mr. Halldin is to purchase the entire 1,818,182 shares from Mr. Robinson by the end of August 2014 (8/31/14). If Halldin transacts this purchase by 8/31/14, Mr. Robinson agrees to split the warrants 50/50 with Mr. Halldin. For example, Mr. Robinson to keep 272,728 warrants; Mr. Halldin to receive 272,727 warrants.

If Mr. Halldin completes the purchase between 9/1/14 and 9/15/14, Mr. Robinson and Mr. Halldin agree to split the warrants 75 (Robinson) / 25 (Halldin). For example, Mr. Robinson would keep 75% of the warrants (409,091 warrants), Mr. Halldin to receive 25% of the warrants (136,364 warrants).

If Mr. Halldin DOES NOT purchase the aforementioned Robinson shares by 9/15/14, Mr. Robinson keeps 100% of the warrants (545,455 warrants).

Additionally, if Mr. Halldin DOES NOT purchase the aforementioned Robinson shares by 9/15/14, Mr. Halldin agrees to do everything within his power and within the limits of the law to get Mr. Robinson nominated and appointed to the Vaccinogen Board of Directors.

This term sheet is binding on the parties. The parties also agree to execute the definitive agreement pursuant to this term sheet when prepared by local counsel. 

/s/ Steven Robinson	/s/ Anders Halldin
Mr. Steven Robinson	Mr. Anders Halldin
2555 N Pearl Street, #1704	Odlingsvagen 10, SE-138 36
Dallas, TX  75201	Sweden
+ 443 280 3153	+ 46 70 868 7566